An Open-label Study to Evaluate the Long-Term Safety and Tolerability of Iptacopan in Patients With Complement Mediated Diseases.
An Open-label, Single-arm, Multicenter Roll-over Extension Program (REP) to Characterize the Long-term Safety and Tolerability of Iptacopan (LNP023) in Patients Who Have Completed a Clinical Trial (Parent Study) in the Iptacopan Pediatric Program
The purpose of this single-arm, multicenter, Phase IIIb roll-over extension study is to assess the long-term safety, tolerability, and efficacy of iptacopan in participants with complement mediated diseases.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Descrição detalhada
This is a Phase IIIb, multicenter, open-label, single-arm roll-over extension study designed to evaluate the long-term safety, tolerability, and efficacy of iptacopan in participants with complement-mediated diseases who have completed a preceding Novartis-sponsored pediatric clinical trial with iptacopan and who, in the opinion of the investigator, continue to derive clinical benefit from treatment. The study will provide post-trial access to iptacopan while continuing to collect long-term safety and efficacy data.
Eligible participants who have completed a pediatric iptacopan parent study will continue to receive open-label iptacopan in this extension study.
Treatment may continue for up to 3 years following the study last patient first visit, or until iptacopan becomes commercially available and/or reimbursed according to local post-trial access requirements, whichever occurs first.
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Estágio
Estágio
- Fase 3
Acesso expandido
Acesso expandido
Disponível
- Disponível: o acesso expandido está atualmente disponível para este tratamento experimental, e os pacientes que não são participantes do estudo clínico podem obter acesso ao medicamento, biológico ou dispositivo médico sendo estudado.
- Não está mais disponível: o acesso expandido estava disponível para esta intervenção anteriormente, mas não está disponível atualmente e não estará disponível no futuro.
- Temporariamente indisponível: o acesso expandido não está disponível atualmente para esta intervenção, mas espera-se que esteja disponível no futuro.
- Aprovado para marketing: A intervenção foi aprovado pela Food and Drug Administration dos EUA para uso público.
Contactos e Locais
Contato de estudo
Contato de estudo
- Nome: Novartis Pharmaceuticals
- Número de telefone: 1-888-669-6682
- E-mail: novartis.email@novartis.com
Estude backup de contato
- Nome: Novartis Pharmaceuticals
- Número de telefone: +41613241111
- E-mail: novartis.email@novartis.com
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
Participants eligible for inclusion in this study must meet all of the following criteria:
- Signed informed consent by parent(s)/legal guardian(s) for the patient must be obtained before enrolling in the roll-over study and receiving study medication. A consent or assent may also be required for some patients depending upon their age and local requirements.
- Male and female participant and has completed the treatment period in the Novartis sponsored pediatric study with iptacopan in any complement mediated disease (e.g., CLNP023I12201 or CLNP023G12301) on study drug.
- Willingness and ability to comply with scheduled visits, treatment plans and any other study procedures.
- Prior vaccinations against Neisseria meningitidis, Streptococcus pneumoniae and Haemophilus influenzae infections should be up to date (i.e. any boosters required administered according to local regulations).
- Per investigator's clinical judgement, the patient may benefit from continued treatment with iptacopan and has been clinically stable on iptacopan prior to enrollment in this extension study.
Exclusion Criteria:
- Any comorbidity or medical condition (including but not limited to any active systemic bacterial, viral or fungal infection or malignancy) that, in the opinion of the investigator, could put the subject at increased risk or potentially confound study data.
- History of recurrent invasive infections caused by encapsulated organisms, such as Neisseria meningitidis, Streptococcus pneumoniae or Haemophilus influenzae.
- Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant from menarche until becoming post-menopausal, unless they are using effective methods of contraception during dosing of study treatment and for 1 week after stopping study treatment. Effective contraception methods include:
- Total abstinence (when this is in line with the preferred and usual lifestyle of the participant). Note that periodic abstinence (e.g., calendar, ovulation, symptothermal, post ovulation methods) and withdrawal are not acceptable methods of contraception.
- Bilateral oophorectomy with or without hysterectomy, total hysterectomy, or bilateral salpingectomy at least 6 weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment are they not considered to be of childbearing potential.
- Bilateral tubal occlusion, bilateral tubal ligation (at least 6 weeks before taking study treatment).
- Barrier methods of contraception: condom or occlusive cap (e.g., diaphragm or cervical/vault caps). For the UK: with spermicidal foam/gel/film/cream/vaginal suppository.
- Use of hormonal contraception methods:
- Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation; oral, intravaginal or transdermal.
- Progestogen-only hormonal contraception associated with inhibition of ovulation: oral, injectable or implantable.
- Intrauterine device (IUD) or intrauterine hormone-releasing system (IUS).
Other protocol-defined inclusion/exclusion criteria may apply.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: Iptacopan
Participants with complement-mediated diseases who have completed a preceding Novartis-sponsored pediatric clinical trial with iptacopan and who continue to derive clinical benefit from treatment will receive open-label iptacopan. Participants >12 years of age will receive iptacopan 200 mg twice daily, and participants aged 2 to <12 years will receive weight-based dosing. |
Participants >12 years of age will receive iptacopan 200 mg twice daily, and participants aged 2 to <12 years will receive weight-based dosing.
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Prazo: From Day 1 through End of Treatment (EOT)/End of Study (EOS), up to approximately 3 years
|
Number of participants with AEs, SAEs and major adverse vascular events (MAVE) including abnormal cardiovascular parameters, safety laboratory parameters and vital signs qualifying and reported as AEs. |
From Day 1 through End of Treatment (EOT)/End of Study (EOS), up to approximately 3 years
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Proportion of participants maintaining stable hemoglobin levels - PNH Indication only
Prazo: From baseline through EOT/EOS, up to approximately 3 years
|
Proportion of participants with paroxysmal nocturnal hemoglobinuria (PNH) maintaining stable hemoglobin (Hb) levels in absence of red blood cell transfusions. Stable Hb is defined as no more than a ≥2 g/dL decrease from baseline. |
From baseline through EOT/EOS, up to approximately 3 years
|
|
Proportion of participants maintaining sustained hemoglobin levels ≥10 g/dL and ≥12 g/dL - PNH Indication only
Prazo: Yearly through EOT/EOS, up to approximately 3 years
|
Proportion of participants with PNH maintaining sustained hemoglobin levels ≥10 g/dL and ≥12 g/dL in the absence of red blood cell transfusions |
Yearly through EOT/EOS, up to approximately 3 years
|
|
Proportion of participants with Hb levels ≥10 g/dL and ≥12 g/dL and LDH ≤1.5 ULN - PNH Indication only
Prazo: From Day 1 through EOT/EOS, up to approximately 3 years
|
Proportion of participants with PNH achieving hemoglobin (Hb) levels ≥10 g/dL and ≥12 g/dL and lactate dehydrogenase (LDH) ≤1.5 times the upper limit of normal (ULN). |
From Day 1 through EOT/EOS, up to approximately 3 years
|
|
Rate of Breakthrough Hemolysis - PNH Indication only
Prazo: From baseline through End of Treatment/End of Study (up to approximately 3 years)
|
Breakthrough hemolysis events in participants with paroxysmal nocturnal hemoglobinuria (PNH). Clinical breakthrough hemolysis is defined based on protocol-specified clinical and laboratory criteria, including evidence of intravascular hemolysis and associated clinical signs/symptoms. The endpoint will be summarized as occurrences per year |
From baseline through End of Treatment/End of Study (up to approximately 3 years)
|
|
Log-transformed ratio to baseline in Urinary Protein-to-Creatinine Ratio (UPCR) - IgAN indication only
Prazo: Baseline and up to approximately 3 years
|
Log-transformed ratio to baseline in UPCR measured using first morning void (FMV) urine samples in participants with immunoglobulin A nephropathy (IgAN). |
Baseline and up to approximately 3 years
|
|
Change from baseline in estimated Glomerular Filtration Rate (eGFR) - IgAN indication only
Prazo: Baseline and up to approximately 3 years
|
Change from baseline in estimated glomerular filtration rate (eGFR) in participants with IgAN. |
Baseline and up to approximately 3 years
|
|
Proportion of participants achieving UPCR <0.5 g/g - IgAN indication only
Prazo: At EOT/EOS, up to approximately 3 years
|
Proportion of participants with IgAN achieving urinary protein-to-creatinine ratio (UPCR) <0.5 g/g. |
At EOT/EOS, up to approximately 3 years
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Diretor de estudo: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças urogenitais
- Doenças Urogenitais Masculinas
- Doenças renais
- Doenças Urológicas
- Doenças Urogenitais Femininas
- Doenças urogenitais femininas e complicações na gravidez
- Doenças autoimunes
- Doenças do sistema imunológico
- Distúrbios da micção
- Manifestações Urológicas
- Doenças Hematológicas
- Glomerulonefrite
- Nefrite
- Condições Patológicas, Sinais e Sintomas
- Sinais e sintomas
- Doenças hemic e linfáticas
- Anemia
- Glomerulonefrite, IGA
- Proteinúria
- iptacopan
Outros números de identificação do estudo
Outros números de identificação do estudo
- CLNP023I12001B
- 2026-525677-39 (Número EudraCT)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .